161 related articles for article (PubMed ID: 32454863)
21. Brain natriuretic peptide for prevention of contrast-induced nephropathy after percutaneous coronary intervention or coronary angiography.
Liu JM; Xie YN; Gao ZH; Zu XG; Li YJ; Hao YM; Chang L
Can J Cardiol; 2014 Dec; 30(12):1607-12. PubMed ID: 25418218
[TBL] [Abstract][Full Text] [Related]
22. Inverse correlation between left ventricular end-diastolic pressure and contrast-induced nephropathy in patients undergoing percutaneous coronary intervention.
Gu G; Xing H; Zhou Y; Cui W
Clin Exp Nephrol; 2018 Aug; 22(4):808-814. PubMed ID: 29196838
[TBL] [Abstract][Full Text] [Related]
23. Efficacy of alprostadil in preventing contrast-induced nephropathy in patients undergoing percutaneous coronary intervention: A multicenter prospective randomized controlled trial.
Liang M; Yang S; Fu N; Lu C; Tian F; Xing X; Lin W; Liu J
Catheter Cardiovasc Interv; 2018 Mar; 91(4):742-750. PubMed ID: 29024304
[TBL] [Abstract][Full Text] [Related]
24. Effect of diabetes blood-stasis syndrome and Xuefu Zhuyu decoction on ROS-ERK1/2 signaling pathway in rat retina Müller cells.
Ye X; Ren H; Jiang T; Zhang T; Li G
Cytotechnology; 2020 Apr; 72(2):303-314. PubMed ID: 32112164
[TBL] [Abstract][Full Text] [Related]
25. Prediction of contrast-induced nephropathy in diabetics undergoing elective percutaneous coronary intervention: role of the ratio of contrast medium volume to estimated glomerular filtration rate.
Wang XC; Fu XH; Wang YB; Jia XW; Wu WL; Gu XS; Zhang J; Su JL; Hao GZ; Jiang YF; Fan WZ; Li SQ
Chin Med J (Engl); 2011 Mar; 124(6):892-6. PubMed ID: 21518598
[TBL] [Abstract][Full Text] [Related]
26. Efficacy of nicorandil treatment for prevention of contrast-induced nephropathy in high-risk patients undergoing cardiac catheterization: A prospective randomized controlled trial.
Iranirad L; Hejazi SF; Sadeghi MS; Jang SA
Cardiol J; 2017; 24(5):502-507. PubMed ID: 28281738
[TBL] [Abstract][Full Text] [Related]
27. Metabolic Profiling Analysis of Patients With Coronary Heart Disease Undergoing Xuefu Zhuyu Decoction Treatment.
Tao T; He T; Wang X; Liu X
Front Pharmacol; 2019; 10():985. PubMed ID: 31551786
[TBL] [Abstract][Full Text] [Related]
28. [Clinical study on compatibility and dismantlement of Xuefu Zhuyu decoction].
Wang J; Jing L; Zhong JB; Wang YY; Ma LH; Liu JG
Zhongguo Zhong Yao Za Zhi; 2004 Aug; 29(8):803-7. PubMed ID: 15506300
[TBL] [Abstract][Full Text] [Related]
29. Impact of Chronic Statin Therapy on Postprocedural Contrast-Induced Nephropathy in Patients Undergoing Non-Emergent Percutaneous Coronary Intervention.
Chanin JM; Yang DC; Haider MA; Swaminathan RV; Kim LK; Charitakis K; Tanoue M; Minutello RM; Gade CL; Singh HS; Bergman G; Wong SC; Feldman DN
J Invasive Cardiol; 2015 Nov; 27(11):490-6. PubMed ID: 25999136
[TBL] [Abstract][Full Text] [Related]
30. Effect of ligustrazine on preventing contrast-induced nephropathy in patients with unstable angina.
Ye Z; Lu H; Su Q; Xian X; Li L
Oncotarget; 2017 Nov; 8(54):92366-92374. PubMed ID: 29190922
[TBL] [Abstract][Full Text] [Related]
31. Prevention of contrast-induced nephropathy with prostaglandin E1 in high-risk patients undergoing percutaneous coronary intervention.
Li WH; Li DY; Qian WH; Liu JL; Xu TD; Zhu H; He HY
Int Urol Nephrol; 2014 Apr; 46(4):781-6. PubMed ID: 24570327
[TBL] [Abstract][Full Text] [Related]
32. Impact of minimum contrast media volumes during elective percutaneous coronary intervention for prevention of contrast-induced nephropathy in patients with stable coronary artery disease.
Ebisawa S; Kurita T; Tanaka N; Nasu K; Kimura M; Ito T; Kinoshita Y; Tsuchikane E; Terashima M; Suzuki T
Cardiovasc Interv Ther; 2016 Jan; 31(1):13-20. PubMed ID: 26001976
[TBL] [Abstract][Full Text] [Related]
33. Insulin Resistance Increases the Risk of Contrast-Induced Nephropathy in Patients Undergoing Elective Coronary Intervention.
Li Y; Liu Y; Shi D; Yang L; Liang J; Zhou Y
Angiology; 2016 Feb; 67(2):139-45. PubMed ID: 25843952
[TBL] [Abstract][Full Text] [Related]
34. Analysis of the risk factors for contrast-induced nephropathy in over-aged patients receiving coronary intervention.
Pan HC; Wu XH; Wan QL; Liu And BH; Wu XS
Exp Biol Med (Maywood); 2018 Aug; 243(12):970-975. PubMed ID: 30299175
[TBL] [Abstract][Full Text] [Related]
35. CHA2DS2-VASC score as a preprocedural predictor of contrast-induced nephropathy among patients with chronic total occlusion undergoing percutaneous coronary intervention: a single-center experience.
Wang Y; Zhao HW; Zhang XJ; Chen BJ; Yu GN; Hou AJ; Luan B
BMC Cardiovasc Disord; 2019 Mar; 19(1):74. PubMed ID: 30922230
[TBL] [Abstract][Full Text] [Related]
36. Contrast-Induced Nephropathy After Percutaneous Coronary Intervention for Chronic Total Occlusion Versus Non-Occlusive Coronary Artery Disease.
Demir OM; Lombardo F; Poletti E; Laricchia A; Beneduce A; Maccagni D; Slavich M; Giannini F; Carlino M; Margonato A; Cappelletti A; Colombo A; Azzalini L
Am J Cardiol; 2018 Dec; 122(11):1837-1842. PubMed ID: 30292337
[TBL] [Abstract][Full Text] [Related]
37. Protective effects of anisodamine on renal function in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention.
Wang Y; Fu X; Wang X; Jia X; Gu X; Zhang J; Su J; Hao G; Jiang Y; Fan W; Wu W; Li S
Tohoku J Exp Med; 2011 Jun; 224(2):91-7. PubMed ID: 21597242
[TBL] [Abstract][Full Text] [Related]
38. Recombinant Brain Natriuretic Peptide for the Prevention of Contrast-Induced Nephropathy in Patients with Chronic Kidney Disease Undergoing Nonemergent Percutaneous Coronary Intervention or Coronary Angiography: A Randomized Controlled Trial.
Liu J; Xie Y; He F; Gao Z; Hao Y; Zu X; Chang L; Li Y
Biomed Res Int; 2016; 2016():5985327. PubMed ID: 26949703
[TBL] [Abstract][Full Text] [Related]
39. Risk scoring system for prediction of contrast-induced nephropathy in patients with pre-existing renal impairment undergoing percutaneous coronary intervention.
Chong E; Shen L; Poh KK; Tan HC
Singapore Med J; 2012 Mar; 53(3):164-9. PubMed ID: 22434288
[TBL] [Abstract][Full Text] [Related]
40. Effect of hydration with or without n-acetylcysteine on contrast induced nephropathy in patients undergoing coronary angiography and percutaneous coronary intervention.
Awal A; Ahsan SA; Siddique MA; Banerjee S; Hasan MI; Zaman SM; Arzu J; Subedi B
Mymensingh Med J; 2011 Apr; 20(2):264-9. PubMed ID: 21522098
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
